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ﬂammatory effects of the allogeneic graft and subsequent
GVHD and its therapy may play a role.
Methods: Retrospective review of medical records of 164
survivors of allogeneic HSCT between 1993 and 2010,
currently followed at the long term follow up clinic to
determine the incidence and risk factors associated with
metabolic syndrome. Metabolic syndrome was deﬁned as
clustering of risk factors for cardiovascular disease charac-
terized by abdominal obesity, atherogenic dyslipidemia,
elevated blood pressure, insulin resistance, and a proin-
ﬂammatory and prothrombotic state.
Results: Patient characteristics are summarized in Table 1.
The prevalence of metabolic syndrome was 7% in our
patient cohort. Six patients had BMI >25, 4 between 20
and 25, one <20. The prevalence rates of hyper-
triglyceridemia and microalbuminuria were 91% and 64%
respectively. Other derangements in the lipid proﬁle
included elevated total cholesterol, low HDL and high to
normal LDL in 9 patients. Thirty-six percent of the patients
had hypothyroidism and insulin resistance. Three out of the
11 survivors with metabolic syndrome had hypertension
and were being treated for it. 73% of the patients are being
followed up in preventive cardiology or endocrinology clinic.Table 1.
Patient Characteristics Number (percentages)
(n¼11)
Age at Transplant (years)
Median 6
Range 0-15
Gender
M 4 (36%)
F 7 (64%)
Ethnicity
Caucasian 5 (45%)
Hispanic 5 (45%)
Others 1 (9%)
Primary Diagnosis
Malignancy 9 (82%)
Non-Malignancy 2 (18%)
Transplant (HPCT) Characteristics
Donor
Related Donor 9 (82%)
Alternative Donor 2 (18%)
HLA Disparity
0-1 loci 11
2-3 loci 0
4-5 loci 0
Stem Cell Source
PBSC 6 (55%)
BM 4 (36%)
Cord 1 (9%)
Conditioning
Myeloablative MAC 11
Reduced Intensity RIC 0
Radiation
TBI (12 Gy, 1.5 Gy fractions) 7 (64%)
Cranial 4 (36%)
Testicular 1 (9%)
Spinal 1 (9%)
GVHD prophylaxis
Cyclosporine based 11 (100%)
Tacrolimus based 0 (0%)
+ ATG 2 (18%)
+ MTX 8 (73%)
Transplant Complications
aGVHD 2 (18%)
cGVHD 5 (45%)
GVHD treatment
Steroids 6 (54%)
ECP 4 (36%)
Others 6 (54%)Conclusions: The prevalence of metabolic syndrome in our
study cohort was more than the general pediatric population
(3.3%). Most of the patients who developed metabolic syn-
drome had been treated with radiation and had a diagnosis
of hematological malignancy. Hypertriglyceridemia and
microalbuminuria were clinical characteristics common to
most patients.
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Bronchiolitis obliterans syndrome (BOS) is a serious late
complication of allogeneic hematopoietic cell trans-
plantation (HCT) with poorly characterized risk factors and
natural history due to disease rarity. We describe the
prevalence of potential risk factors, diagnostic characteris-
tics, and natural history of 36 individuals enrolled on a
multicenter prospective trial (NCT01307462) to treat new
onset BOS after HSCT. BOS was diagnosed using modiﬁed
2005 NIH consensus criteria (FEV1<75% predicted, FEV1/
VC<0.7, and >10% FEV1 decline from pre-HCT). Possible risk
factors for lung injury included cigarette exposure in 47%
(17/36), while history of asthma or chronic obstructive lung
disease (6%) and idiopathic pneumonia syndrome (6%) were
rare. The most common treatment exposures associated
with pulmonary toxicity included cyclophosophamide
(69%), ﬂudarabine (44%), busulfan (42%) and radiation (42%).
Documented infection potentially associated with pulmo-
nary inﬂammation prior to BOS diagnosis included respi-
ratory viruses in 12/36 (33%); 4 had CMV viremia. Median
time from HCT to BOS diagnosis was 546 days (range 157-
4008). The diagnostic workup was prompted by patient-
reported symptoms in nearly half of the cohort (17/36, 47%)
and by screening pulmonary function tests (PFT) in the
remainder (53%), with median FEV1% predicted of 46.5
(range 26-67). There was a trend toward higher mean FEV1
in patients with BOS detected by PFT screening, but this was
not statistically signiﬁcant (50.2 vs 43.1, p¼0.13). While
most evaluations included chest CT (89%), few underwent
bronchoscopy (28%) or surgical biopsy (6%). Eye (68 %),
skin (56%) and mouth (56%) were the most common con-
current manifestations of chronic graft-versus-host disease
(cGVHD); 3 (9%) did not have extrapulmonary cGVHD signs
at onset of BOS. Eleven (31%) subjects required supple-
mental oxygen after BOS diagnosis and 5 (14%) currently use
oxygen. Twenty (56%) subjects were hospitalized after their
diagnosis of BOS at least once, most commonly for
Figure. Kaplan-Meier Survival Estimate, n¼36.
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more respiratory tract infections treated with antimicro-
bials, most often due to Pseudomonas spp (n¼7), Aspergillus
spp (n¼5), inﬂuenza (n¼4) and parainﬂuenza (n¼4). Overall
survival of the cohort was 72% with a median follow-up of
16 months (range 3-32). The primary causes of death in 8
subjects were complications of cGVHD (n¼5) including BOS,
relapse (n¼2), and infection (n¼1). These data suggest the
following: there may be exposures that are risk factors for
BOS after HCT, lung function loss is moderately severe at
diagnosis whether prompted by symptoms or PFT, and pa-
tients with BOS have high morbidity and mortality directly
associated with cGVHD of the lung, even when treated early
after diagnosis.
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Topic Signiﬁcance & Study Purpose/Background/
Rationale: The transition from transplant center to local
oncologist and from local housing to home demands both
practical and emotional consideration. Transplant Nurse
Coordinators (TNCs) and Clinical Social Workers (CSWs) are
in a unique position to help patients and caregivers in this
transition. With proper education, patients and caregivers
are better equipped to handle discharge. The use of a group
modality allows patients and caregivers the opportunity to
learn from one another.
Methods, Intervention, & Analysis: TNCs and CSWs met to
develop a program to address the transition from transplant
center care to home. Content input was secured from other
nurses, social workers, and physicians in the outpatient BMT
program based on the perceived need for support of pa-
tients during this critical time. A group modality was chosen
in an effort to utilize peer learning and support.
All patients who underwent an allogeneic transplant
were scheduled to attend the program prior to dischargefrom the transplant center, between day +60 and day +90. A
slide presentation was developed and focused on the
following areas: communication between the transplant
center and the local oncologist, necessary precautions, rec-
ommended follow-up care, practical aspects of insurance,
employment, ﬁnances and emotional concerns including
managing anxiety, depression, and adjusting to the “new
normal.” Group discussions and reﬂection of the transplant
experience and future goals were facilitated by the TNCs and
CSWs. Evaluations were obtained from each participant at
their next clinic visit.
Findings & Interpretations: Overall, patients and caregivers
rated the group experience and information provided as
informative and thought provoking. 97% of participants
“strongly agreed/agreed” that the topics presented assisted
them in planning their discharge from both a practical and
emotional perspective. 93% reported feeling comfortable
participating in the group discussions.
Discussion & Implications: The beneﬁt of an interdisci-
plinary model between TNCs and CSWs provides a
broad perspective relative to BMT patients transitioning
home. The use of discussion, as well as slide presentation,
helps to individualize education for participants,
creates an environment for discussing questions and
concerns, and allows patients and caregivers to share
experiences and receive support. Another class relative to
the period of post-transplant days +30 to +45 is under
consideration.217
Oral Ribavirin for the Treatment of Respiratory Syncytial
Virus Infection in Allogeneic Stem Cell Transplant
Recipients-Utility of the Immunodeﬁciency Scoring Index
for Risk Stratiﬁcation
Moussab Damlaj 1, Gabriel Bartoo 2, Desire Gijima 3,
Shahrukh Hashmi 1, Mark R. Litzow 1, William Hogan 1,
Mrinal Patnaik 1. 1 Division of Hematology, Mayo Clinic,
Rochester, MN; 2Department of Pharmacy Services, Mayo
Clinic, Rochester, MN; 3University of Iowa, Iowa City, IA
Background: Respiratory syncytial virus (RSV) infection is
a serious complication post allogeneic stem cell trans-
plant. Aerosolized ribavirin is a commonly used therapy;
however, oral ribavirin is an alternative with many ad-
vantages. There is paucity in literature regarding treat-
ment outcomes using the oral form. Recently, the
immunodeﬁciency scoring index (ISI) was derived from
the largest reported RSV cohort to date using aerosolized
ribavirin.
Objectives: We sought to investigate whether the ISI is
predictive of mortality and lower respiratory tract infection
(LRTI) progression in an independent cohort of RSV infected
allogeneic transplant recipients treated with oral ribavirin
therapy.
Methods: Consecutive patients diagnosed with RSV infec-
tion seen at Mayo Clinic Rochester from 2008e2014 were
identiﬁed. Clinical and pathologic data were retrospectively
abstracted after obtaining IRB approval. The ISI (Blood 2014)
score was calculated for each patient. Survival estimates
were done using the Kaplan-Meier method and log rank test
was used to compare the risk groups.
Results: A total of 53 patients tested positive for RSV infec-
tion. Twenty-eight were female (53%) and the median age at
RSV infection was 55 years (range 15-71). Stem cell source
was peripheral blood in 44 (83%), 7 bonemarrow (13%) and 2
were double cord (4%). Indication for transplant was myeloid
